Literature DB >> 25187765

Interventional neurology: a personal road map.

Anthony J Furlan1.   

Abstract

Year:  2012        PMID： 25187765      PMCID： PMC4031763          DOI： 10.1159/000338357

Source DB:  PubMed          Journal:  Interv Neurol        ISSN： 1664-5545


× No keyword cloud information.
  13 in total

1.  Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

Authors:  A Furlan; R Higashida; L Wechsler; M Gent; H Rowley; C Kase; M Pessin; A Ahuja; F Callahan; W M Clark; F Silver; F Rivera
Journal:  JAMA       Date:  1999-12-01       Impact factor: 56.272

2.  Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.

Authors:  I L Katzan; A J Furlan; L E Lloyd; J I Frank; D L Harper; J A Hinchey; J P Hammel; A Qu; C A Sila
Journal:  JAMA       Date:  2000-03-01       Impact factor: 56.272

3.  Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke.

Authors:  G J del Zoppo; K Poeck; M S Pessin; S M Wolpert; A J Furlan; A Ferbert; M J Alberts; J A Zivin; L Wechsler; O Busse
Journal:  Ann Neurol       Date:  1992-07       Impact factor: 10.422

4.  Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset.

Authors:  E C Haley; D E Levy; T G Brott; G L Sheppard; M C Wong; G L Kongable; J C Torner; J R Marler
Journal:  Stroke       Date:  1992-05       Impact factor: 7.914

5.  PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

Authors:  G J del Zoppo; R T Higashida; A J Furlan; M S Pessin; H A Rowley; M Gent
Journal:  Stroke       Date:  1998-01       Impact factor: 7.914

Review 6.  Recommendations for the establishment of primary stroke centers. Brain Attack Coalition.

Authors:  M J Alberts; G Hademenos; R E Latchaw; A Jagoda; J R Marler; M R Mayberg; R D Starke; H W Todd; K M Viste; M Girgus; T Shephard; M Emr; P Shwayder; M D Walker
Journal:  JAMA       Date:  2000-06-21       Impact factor: 56.272

7.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

8.  Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

Authors:  Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni
Journal:  N Engl J Med       Date:  2008-09-25       Impact factor: 91.245

9.  Bringing the hospital to the patient: first treatment of stroke patients at the emergency site.

Authors:  Silke Walter; Panagiotis Kostpopoulos; Anton Haass; Stefan Helwig; Isabel Keller; Tamara Licina; Thomas Schlechtriemen; Christian Roth; Panagiotis Papanagiotou; Anna Zimmer; Julio Viera; Julio Vierra; Heiko Körner; Kathrin Schmidt; Marie-Sophie Romann; Maria Alexandrou; Umut Yilmaz; Iris Grunwald; Darius Kubulus; Martin Lesmeister; Stephan Ziegeler; Alexander Pattar; Martin Golinski; Yang Liu; Thomas Volk; Thomas Bertsch; Wolfgang Reith; Klaus Fassbender
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

10.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.